Corticosteroids for treating optic neuritis-Reference-Cited by-同舟云学术

Corticosteroids for treating optic neuritis

Published:2015-08-14 Issue:11 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Gal Robin L¹,Vedula S Swaroop²,Beck Roy¹

Affiliation:

1. Jaeb Center for Health Research; Tampa Florida USA

2. Johns Hopkins University; Baltimore Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference90 articles.

1. Corticosteroids do not prevent optic nerve atrophy following optic neuritis;Hickman;Journal of Neurology, Neurosurgery and Psychiatry,2003

2. Double-blind controlled trial of methylprednisolone treatment for acute optic neuritis: 6-month follow-up with visual evoked potential measurement;Jones;Multiple Sclerosis,1996

3. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis;Kapoor;Neurology,1998

4. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis;Menon;Indian Journal of Ophthalmology,2007

5. Optic neuritis treatment trial: Contrast sensitivity; assessment and results;Tabuchi;Neuro-Ophthalmology Japan,1998

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroprotective effects of Gypenosides: A review on preclinical studies in neuropsychiatric disorders;European Journal of Pharmacology;2024-09

2. Unilateral optic neuritis following intravenous metronidazole: a case report;Toxicology Communications;2024-05-30

3. A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis;Cureus;2024-03-13

4. Tissue Hypoxia and Associated Innate Immune Factors in Experimental Autoimmune Optic Neuritis;International Journal of Molecular Sciences;2024-03-06

5. Evaluating Relapse Knowledge in People with Multiple Sclerosis: A Cross-Sectional Study on the Development and Validation of the Relapse Knowledge Questionnaire;Multiple Sclerosis and Related Disorders;2024-03